Judah Frommer Analyst PerformanceSenior Equity Research Analyst, SMid Cap Biotech at Morgan StanleyJudah Frommer is a stock analyst at Morgan Stanley focused in the healthcare sector, covering 33 publicly traded companies. Over the past year, Judah Frommer has issued 43 stock ratings, including buy, hold, and sell recommendations. While full access to Judah Frommer's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Judah Frommer's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings105 Last 8 YearsBuy Recommendations68.27% 71 Buy RatingsCompanies Covered33 Unique Companies Ratings Distribution104RatingsDistribution of strong buy, buy, hold, and sell ratings by Judah Frommer.RatingPercentageCount Strong Buy0.0%0 ratings Buy68.3%71 ratings Hold28.8%29 ratings Sell2.9%3 ratingsOut of 104 total stock ratings issued by Judah Frommer at Morgan Stanley, the majority (68.3%) have been Buy recommendations, followed by 28.8% Hold and 2.9% Sell.Best & Worst CallsBest Call0000.0%TRVIAug 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ATAINov 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ81.8% of companies on NASDAQ27 companiesNYSE18.2% of companies on NYSE6 companiesJudah Frommer, an analyst at Morgan Stanley, currently covers 33 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare23 companies69.7%Consumer Staples7 companies21.2%Consumer Discretionary2 companies6.1%Miscellaneous1 company3.0%Judah Frommer of Morgan Stanley specializes in stock coverage within the Healthcare sector, with additional focus on Consumer Staples and Consumer Discretionary companies.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY18 companies54.5%CONSUMER STAPLES DISTRIBUTION & RETAIL7 companies21.2%PHARMACEUTICALS5 companies15.2%Miscellaneous1 company3.0%BROADLINE RETAIL1 company3.0%SPECIALTY RETAIL1 company3.0% Judah Frommer's Ratings History at Morgan Stanley Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCLDXCelldex Therapeutics9/10/2026Boost Price Target$38.62$50.00Overweight$0.0000.00% ROIATTOAttovia Therapeutics8/31/2026Initiated Coverage$20.70$39.00Overweight$0.0000.00% ROIQTTBQ32 Bio8/24/2026Initiated Coverage$15.97$34.00Overweight$0.0000.00% ROIZBIOZenas BioPharma8/14/2026Boost Price Target$29.96$32.00Equal Weight$0.0000.00% ROIBLTEBelite Bio8/14/2026Boost Price Target$164.59$206.00Overweight$0.0000.00% ROIAVLNAvalyn Pharma8/13/2026Boost Price Target$37.38$57.00Overweight$0.0000.00% ROIBCAXBicara Therapeutics8/11/2026Boost Price Target$23.76$39.00Overweight$0.0000.00% ROILKFTLakefront Biotherapeutics American Depositary Shares8/11/2026Lower Price Target$27.99$26.00Equal Weight$0.0000.00% ROIIMMXImmix Biopharma8/11/2026Lower Price Target$10.18$19.00Overweight$0.0000.00% ROITRVITrevi Therapeutics8/7/2026Reiterated Rating$18.28$23.00Overweight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. CLDXCelldex Therapeutics8/7/2026Boost Price Target$41.69$46.00Overweight$0.0000.00% ROIKYMRKymera Therapeutics8/6/2026Reiterated Rating$104.78$135.00Overweight$0.0000.00% ROICMPSCompass Pathways8/6/2026Boost Price Target$13.53$18.00Overweight$0.0000.00% ROIPTCTPTC Therapeutics7/31/2026Boost Price Target$75.52$104.00Overweight$0.0000.00% ROIINCYIncyte7/29/2026Set Price Target$128.66$119.00$0.0000.00% ROIABVXAbivax7/24/2026Reiterated Rating$129.24$180.00Overweight$0.0000.00% ROIINCYIncyte7/23/2026Boost Price Target$117.50$104.00Equal Weight$0.0000.00% ROICLDXCelldex Therapeutics7/22/2026Lower Price Target$34.31$40.00Overweight$0.0000.00% ROICMPSCompass Pathways7/7/2026Reiterated Rating$12.89$17.00Overweight$0.0000.00% ROIEVMNEvommune6/30/2026Lower Price Target$15.08$26.00Overweight$0.0000.00% ROIENGNenGene6/18/2026Downgrade$1.74$3.00Underweight$0.0000.00% ROIABVXAbivax6/2/2026Lower Price Target$129.69$132.00Overweight$0.0000.00% ROIAVLNAvalyn Pharma5/26/2026Initiated Coverage$28.84$53.00Overweight$0.0000.00% ROIZBIOZenas BioPharma5/14/2026Boost Price Target$19.11$22.00Equal Weight$0.0000.00% ROIBCAXBicara Therapeutics5/12/2026Boost Price Target$22.57$37.00Overweight$0.0000.00% ROIEVMNEvommune5/11/2026Boost Price Target$24.54$55.00Overweight$0.0000.00% ROITRVITrevi Therapeutics5/6/2026Reiterated Rating$14.66$20.00Overweight$0.0000.00% ROIKLRSKalaris Therapeutics4/16/2026Initiated Coverage$5.87$14.00Overweight$0.0000.00% ROIIMMXImmix Biopharma3/25/2026Initiated Coverage$8.57$20.00Overweight$0.0000.00% ROITRVITrevi Therapeutics3/18/2026Lower Price Target$10.80$18.00Overweight$0.0000.00% ROIZBIOZenas BioPharma3/17/2026Boost Price Target$23.23$21.00Equal Weight$0.0000.00% ROIRGNXREGENXBIO3/5/2026Lower Price Target$8.72$17.00Overweight$0.0000.00% ROIAGMBAgomAb Therapeutics3/3/2026Initiated Coverage$16.21$28.00Overweight$0.0000.00% ROIBLTEBelite Bio3/3/2026Boost Price Target$173.12$201.00Overweight$0.0000.00% ROIEVMNEvommune2/18/2026Reiterated Rating$31.12$54.00Overweight$0.0000.00% ROIGMABGenmab A/S2/16/2026Initiated Coverage$30.03$34.00Equal Weight$0.0000.00% ROIRGNXREGENXBIO2/10/2026Lower Price Target$8.92$18.00Overweight$0.0000.00% ROIABVXAbivax1/9/2026Boost Price Target$115.49$145.00Overweight$0.0000.00% ROIBLTEBelite Bio1/6/2026Initiated Coverage$159.42$191.00Overweight$0.0000.00% ROIZBIOZenas BioPharma1/5/2026Downgrade$13.62$19.00Equal Weight$0.0000.00% ROIThey didn't warn anyone in 1971. This time someone is warning you. (Ad)On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.Request the free guide in 30 seconds and get positioned nowEVMNEvommune12/1/2025Initiated Coverage$20.71$36.00Overweight$0.0000.00% ROITRVITrevi Therapeutics11/14/2025Boost Price Target$11.46$19.00Overweight$0.0000.00% ROIZBIOZenas BioPharma11/13/2025Boost Price Target$35.80$37.00Overweight$0.0000.00% ROIABVXAbivax9/12/2025Boost Price Target$83.12$101.00Overweight$000.0000.00% ROITRVITrevi Therapeutics8/21/2025Initiated Coverage$7.42$18.00Overweight$00.0000.00% ROIAPLSApellis Pharmaceuticals7/2/2025Boost Price Target$18.25$26.00Equal Weight$0.0000.00% ROICLDXCelldex Therapeutics5/9/2025Lower Price Target$18.79$43.00Overweight$00.0000.00% ROICLDXCelldex Therapeutics3/20/2025Initiated Coverage$19.95$46.00Overweight$00.0000.00% ROIABVXAbivax3/20/2025Reiterated Rating$6.84$12.00Equal Weight$000.0000.00% ROIRGNXREGENXBIO3/14/2025Boost Price Target$6.55$24.00Overweight$0.0000.00% ROILKFTLakefront Biotherapeutics American Depositary Shares2/14/2025Downgrade$25.49$22.00Underweight$00.0000.00% ROIFDMT4D Molecular Therapeutics1/13/2025Lower Price Target$4.80$6.00Underweight$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenWeiss RatingsUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank Aktiengesellschaft Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
